-
New review: the nocebo effect may contribute to treatment failures when patients are switched from an originator
#biologic to a#biosimilar. Better patient education is among the authors' recommendations https://www.centerforbiosimilars.com/news/nocebo-effect-may-have-role-in-some-treatment-failures-adverse-events-in-nonmedical-switching- … -
@RnDSystems is continuing to expand its range of research grade#biosimilar antibodies. We now offer 154 biosimilar antibodies covering 20 targets that are conjugated or unconjugated to fit your needs. View products: https://bit.ly/2u3r6iR pic.twitter.com/xsVQ3z0cyr
-
The
#biosimilar market in#China is projected to quadruple from USD 2 billion in 2018 to USD 8.1 billion in 2025.http://ow.ly/Vofp50ye1t9 -
#PolicyDeciphered:@US_FDA and@FTC draw a line on anticompetitive practices in the complex#biosimilar market. Read more: http://bit.ly/39bK99K pic.twitter.com/y8RMHvkjWp
-
The regulatory submission is supported by a comprehensive data package demonstrating biosimilarity with PF-05280586 to reference rituximab, including results from the REFLECTIONS B3281006 study
#biosimilar http://ow.ly/JJfZ50yczsD -
Do you ever wonder where the US
#biosimilars market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the#biosimilar industry. https://bit.ly/2SihQzq -
View the top ten
#genericdrugs ranked by savings. The presence in the market of FDA-approved safe and effective generic and#biosimilar medicines saves America's patients more money every year. http://bit.ly/GRxBiosimsSavingsReport …#GRxBiosimsSavingsReportpic.twitter.com/rtYmr5oWtU
-
AAM and its
@BiosimsCouncil looks forward to continuing to work closely with the Administration to increase patient access to critical and live-saving treatments, including#biosimilar#insulin.#SOTU2020
-
.
@US_FDA,#FTC pledge cooperation to boost#biosimilar competition https://www.centerforbiosimilars.com/news/fda-ftc-pledge-close-cooperation-to-create-biosimilar-competition … -
The European Medicines Agency’s Committee for Medicinal Products for Human Use has a positive opinion for a Marketing Authorization Application for the rituximab
#biosimilar PF-05280586 for non-Hodgkin lymphoma, CLL, RA, GPA, MPA, and pemphigus vulgaris http://ow.ly/cQrG50ycz6T -
"...claiming that a
#biosimilar is, in general, less safe or less effective than the reference product ...simply because the#biosimilar is licensed for fewer indications than the reference product would be misleading"Prikaži ovu nit -
"...representations or suggestions that create an impression that a
#biosimilar is not highly similar to its reference product are likely to be false or misleading."Prikaži ovu nit -
FDA Guidance on
#Biologic and#Biosimilar misinformation: "..representing or suggesting that a reference product is safer or more effective than its#biosimilar product... are likely to be false or misleading" https://www.fda.gov/media/134862/download …pic.twitter.com/E9GBFxGxF4
Prikaži ovu nit -
Want to know more about future
#biosimilar opportunities? Join Aurelio Arias at his presentation on the 'Global Outlook for Biologics and Biosimilars' at#pharmapackeu 2020 http://bit.ly/2tpdsGq pic.twitter.com/WVViDgaBu8
-
As Ontario considers
#IBD forced#biologic to#biosimilar switch policy, open letter asks@fordnation and@celliottability to review evidence and alternatives to save money@gisociety@diabetescanada@optihealthorg#crohns#colitispic.twitter.com/dBut27CKlX
-
#biosimilar availability in 40 countries@OncoAlert#oncoalerthttps://twitter.com/TheLancetOncol/status/1223229543927906305 …
-
Pfizer Inc. - Pfizer Receives Positive CHMP Opinion of the European Medicines Agency for Oncology
#Biosimilar RUXIENCE™ (rituximab) https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-Receives-Positive-CHMP-Opinion-for-Oncology-Biosimilar-RUXIENCE-rituximab/default.aspx … -
The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion for our third therapeutic
#oncology#biosimilar. Find out more: http://bit.ly/2RIh5Rg -
Read our analysis of a potential subgroup inclusion in a phase III
#biosimilar study & our counterintuitive solution.#UncommonCRO@worldwidetrials http://bit.ly/2RL3sRp pic.twitter.com/0gXc5mtuWL
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.